Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

837332

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	School Milk
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to his Department's 2014 paper Next Steps for Nursery Milk, whether his Department is responsible for the nursery milk scheme.
tabling member constituency	Hampstead and Kilburn
tabling member printed	Tulip Siddiq
uin	126451
answer	answer is ministerial correction date of answer 09/02/2018 answer text <p>Yes.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 09/02/2018 12:06:35 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4518 label Biography information for Tulip Siddiq

837368

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Yorkshire and the Humber
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to support increased provision of emergency beds for mental health crisis patients in Yorkshire and the Humber.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	126487
answer	answer is ministerial correction date of answer 09/02/2018 answer text <p>Significant work is underway to ensure all areas of the country are actively prioritising the provision of crisis response and acute mental health care services.</p><p> </p><p>By 2021, in line with recommendations from the Five Year Forward View for Mental Health all areas should have crisis resolution and home treatment teams which can provide both a 24/7 community-based emergency response and offer intensive home treatment as an alternative to an acute inpatient admission.</p><p> </p><p>We have set an ambition to eliminate inappropriate out of area placements for adult acute mental health care resulting from local bed capacity pressures. All areas have plans in place to ensure that acute mental health inpatient beds are always available to people who need them by 2021.</p><p> </p><p>In Yorkshire and the Humber, work is expected to begin on a new inpatient mental health facility for children and young people at St Mary’s Hospital in 2019. Leeds and York Partnership NHS Foundation Trust already operates disability and mental health services from the site. The new unit will have 18 specialist and four psychiatric intensive care beds.</p><p> </p><p>Humber NHS Foundation Trust is developing a new 11 bed mental health unit in West Hull. The facility will help young people from Hull, East Riding and North and North East Lincolnshire suffering with mental health problems.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 09/02/2018 12:02:52 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4658 label Biography information for Alex Sobel

837398

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood: Contamination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the time taken to award victims of the contaminated blood scandal compensation.
tabling member constituency	Glasgow North East
tabling member printed	Mr Paul Sweeney
uin	126517
answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>A small number of compensation payments have been paid to a number of people affected by infected blood where out of court settlements have been agreed or the courts awarded compensation under the Consumer Protection Act. As liability has not been established in the majority of cases, most support for affected individuals has been and continues to be provided through Government funded ex-gratia payments set up for people who have been affected by HIV and/or hepatitis C through treatment with National Health Service-supplied blood or blood products.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 08/02/2018 17:30:05 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4642 label Biography information for Mr Paul Sweeney

837402

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood: Contamination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what financial arrangements his Department has put place with the Welsh Government to support Welsh victims of the contaminated blood scandal.
tabling member constituency	Dwyfor Meirionnydd
tabling member printed	Liz Saville Roberts
uin	126521
answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>Decisions on levels of support provided to those who were infected in Wales are for the Welsh Ministers to make. On 1 November 2017 a new scheme to support those infected in Wales was launched.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 08/02/2018 17:26:42 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4521 label Biography information for Liz Saville Roberts

837440

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Conversion Therapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an estimate of the number people who have undertaken gay conversion therapy.
tabling member constituency	Washington and Sunderland West
tabling member printed	Mrs Sharon Hodgson
uin	126559
answer	answer is ministerial correction date of answer 09/02/2018 answer text <p>The Department does not hold an estimate of the number of people that have undertaken gay conversion therapy. In 2017, the Government Equalities Office carried out a survey of the experience of lesbian, gay, bisexual and transgender people in the United Kingdom, which included several questions about gay conversion therapy. Whilst not a statistically representative sample, the survey received over 100,000 responses and will help us improve our understanding of the numbers of people who have undergone, or have been offered, gay conversion therapy. This is an issue the Government is keeping under review and we are constantly working towards improving the evidence base.</p><p> </p><p>The Government rejects utterly the notion that sexuality is something to be cured, and condemns gay conversion therapy. The evidence base is clear that conversion therapy is not only ineffective, but is potentially harmful to participants. That is why officials have worked with the main registration and accreditation bodies for psychotherapy and counselling practitioners, including the UK Council for Psychotherapy, to develop a Memorandum of Understanding to help put a stop to this bogus treatment.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 126560 question first answered 09/02/2018 12:05:18 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1521 label Biography information for Mrs Sharon Hodgson

837441

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Conversion Therapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the (a) psychological (b) emotional effect on people undergoing gay conversion therapy.
tabling member constituency	Washington and Sunderland West
tabling member printed	Mrs Sharon Hodgson
uin	126560
answer	answer is ministerial correction date of answer 09/02/2018 answer text <p>The Department does not hold an estimate of the number of people that have undertaken gay conversion therapy. In 2017, the Government Equalities Office carried out a survey of the experience of lesbian, gay, bisexual and transgender people in the United Kingdom, which included several questions about gay conversion therapy. Whilst not a statistically representative sample, the survey received over 100,000 responses and will help us improve our understanding of the numbers of people who have undergone, or have been offered, gay conversion therapy. This is an issue the Government is keeping under review and we are constantly working towards improving the evidence base.</p><p> </p><p>The Government rejects utterly the notion that sexuality is something to be cured, and condemns gay conversion therapy. The evidence base is clear that conversion therapy is not only ineffective, but is potentially harmful to participants. That is why officials have worked with the main registration and accreditation bodies for psychotherapy and counselling practitioners, including the UK Council for Psychotherapy, to develop a Memorandum of Understanding to help put a stop to this bogus treatment.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 126559 question first answered 09/02/2018 12:05:18 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1521 label Biography information for Mrs Sharon Hodgson

837605

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Records: Databases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish NHS Digital's assessment of the performance of EMIS against its service level agreement governing the supply of electronic patient record systems.
tabling member constituency	Easington
tabling member printed	Grahame Morris
uin	126724
answer	answer is ministerial correction date of answer 08/02/2018 answer text <p>I refer the hon. Member to my Written Ministerial Statement to the house on 18 January 2018 <a href="http://www.parliament.uk/business/publications/written-questions-answers-statements/written-statements/?page=1&amp;max=20&amp;questiontype=AllQuestions&amp;house=commons%2clords&amp;uin=HCWS406" target="_blank">HCWS406</a>. On Monday 15 January 2018 EMIS Group PLC notified NHS Digital regarding under-reporting of issues with their general practice clinical systems provided under the General Practice Systems of Choice contract. A detailed investigation by NHS Digital is ongoing, and we will provide a further update to Parliament once this important work is complete.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 08/02/2018 17:28:03 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	3973 label Biography information for Grahame Morris

837625

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Piperacillin/tazobactam
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what rules the Medicines and Healthcare products Regulatory Agency issues on the prescribing of the drug Tazocin; and if he will make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	126744
answer	answer is ministerial correction date of answer 09/02/2018 answer text <p>Tazocin is a specific brand of the antibiotic piperacillin-tazobactam, of which generic formulations are also licensed for use. Tazocin is indicated for the treatment of a range of severe and complicated infections. As with all licensed medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) has evaluated the safety, quality and efficacy of Tazocin in accordance with its licensed use and the balance of benefits and risks is favourable.</p><p> </p><p>The licensed recommendations on the use of Tazocin are described in the Summary of Product Characteristics (SmPC) for prescribers as well as the Patient Information Leaflet (PIL). The possible side effects of use in accordance with the licensed indications and dosages are also listed in the SmPC and PIL.</p><p> </p><p>As with any medicine, healthcare professionals are able to prescribe Tazocin ‘off-label’ at dosages that are not authorised in the SmPC. Off-label use is the responsibility of the prescriber, based on their clinical judgement and the benefits and risks to an individual patient.</p><p> </p><p>The MHRA does not issue guidance on the circumstances under which off-label use of Tazocin may be appropriate, nor has it conducted a study of mortality in patients following off-label use.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 126748 126749 question first answered 09/02/2018 12:01:14 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1528 label Biography information for Sir Mike Penning

837629

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Piperacillin/tazobactam
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, under what circumstances the drug Tazocin can be prescribed to a patient in excess of the licensed maximum strength rate as set by the Medicines and Healthcare products Regulatory Agency; and if he will make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	126748
answer	answer is ministerial correction date of answer 09/02/2018 answer text <p>Tazocin is a specific brand of the antibiotic piperacillin-tazobactam, of which generic formulations are also licensed for use. Tazocin is indicated for the treatment of a range of severe and complicated infections. As with all licensed medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) has evaluated the safety, quality and efficacy of Tazocin in accordance with its licensed use and the balance of benefits and risks is favourable.</p><p> </p><p>The licensed recommendations on the use of Tazocin are described in the Summary of Product Characteristics (SmPC) for prescribers as well as the Patient Information Leaflet (PIL). The possible side effects of use in accordance with the licensed indications and dosages are also listed in the SmPC and PIL.</p><p> </p><p>As with any medicine, healthcare professionals are able to prescribe Tazocin ‘off-label’ at dosages that are not authorised in the SmPC. Off-label use is the responsibility of the prescriber, based on their clinical judgement and the benefits and risks to an individual patient.</p><p> </p><p>The MHRA does not issue guidance on the circumstances under which off-label use of Tazocin may be appropriate, nor has it conducted a study of mortality in patients following off-label use.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 126744 126749 question first answered 09/02/2018 12:01:14 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1528 label Biography information for Sir Mike Penning

837630

registered interest
date	05/02/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Piperacillin/tazobactam
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what studies his Department or its agencies have undertaken into the effects on the mortality rate of patients of the use of the drug Tazocin when prescribed in excess of the licensed maximum strength rate as set by the Medicines and Healthcare products Regulatory Agency; and if he will make a statement.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	126749
answer	answer is ministerial correction date of answer 09/02/2018 answer text <p>Tazocin is a specific brand of the antibiotic piperacillin-tazobactam, of which generic formulations are also licensed for use. Tazocin is indicated for the treatment of a range of severe and complicated infections. As with all licensed medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) has evaluated the safety, quality and efficacy of Tazocin in accordance with its licensed use and the balance of benefits and risks is favourable.</p><p> </p><p>The licensed recommendations on the use of Tazocin are described in the Summary of Product Characteristics (SmPC) for prescribers as well as the Patient Information Leaflet (PIL). The possible side effects of use in accordance with the licensed indications and dosages are also listed in the SmPC and PIL.</p><p> </p><p>As with any medicine, healthcare professionals are able to prescribe Tazocin ‘off-label’ at dosages that are not authorised in the SmPC. Off-label use is the responsibility of the prescriber, based on their clinical judgement and the benefits and risks to an individual patient.</p><p> </p><p>The MHRA does not issue guidance on the circumstances under which off-label use of Tazocin may be appropriate, nor has it conducted a study of mortality in patients following off-label use.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price grouped question UIN 126744 126748 question first answered 09/02/2018 12:01:14 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1528 label Biography information for Sir Mike Penning